ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Early Stage

ADAURA: Data is Only Part of the Story

on: January 29, 2021In: Early Stage
ADAURA: Data is Only Part of the Story

Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has […] Read more


Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC

Kara Nyberg, PhD
on: January 27, 2021In: Early Stage, WCLC 2020 Archive
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected
            EGFR-Mutated NSCLC

The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or […] Read more

Redefining Good Quality Resections in NSCLC

on: January 26, 2021In: Early Stage, WCLC 2020 Archive
Redefining Good Quality Resections in NSCLC

Curative-intent resections for NSCLC often fail. Approximately 20% to 40% of patients with lung cancer who undergo curative-intent resection, experience a relapse, and die within 4 years. One key factor […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy